Close this search box.

Synaffix entered into licensing agreement with ABL Bio Inc.

Synaffix entered agreement with ABL Bio Inc.

AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases.

Synaffix will receive an upfront payment, milestone payments and tiered royalties on net sales of resulting products and will be responsible for manufacturing components specifically related to its proprietary technologies. ABL Bio will be responsible for the research, development, and commercialization of any bispecific ADCs developed under the agreement. Following the recent acquisition of Synaffix by Lonza, ABL Bio considers Lonza as a potential partner for clinical production of the antibody to be used in the first program, underscoring the strong and immediate post-merger synergies. The first program will commence upon deal signature with options exercisable for up to two additional programs over time.

ADCs prepared from bispecific antibodies are designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell. By designing ADCs that must bind to two different targets in order to produce a therapeutic effect, it is possible to target cancerous cells more specifically and further improve the therapeutic safety profile. 

Peter van de Sande, Head of Synaffix, said: “Under our collaboration with ABL Bio, we will focus onthe discovery and development of cutting-edge bispecific ADCs. It underlines the vast and growing potential of Synaffix’s innovative technology platforms for engineering smart, targeted biologics that deliver therapeutic payloads with best-in-class therapeutic index. Following our recent acquisition by Lonza, our collective capabilities now enable a more comprehensive offering that extends to essential early development and production services.”

Sang Hoon Lee, PhD, Chief Executive Officer of ABL Bio, added: “We are excited by the potential of this partnership with Synaffix, allowing us to further build on our understanding of the potential of this new area of ADC research combined with Synaffix’s award-winning ADC technology platform. The speed of R&D is increasingly important to secure a foothold in the burgeoning ADC market. With close collaboration between ABL Bio and Synaffix, I’m confident that we will achieve remarkable results in the ADC field.”

Synaffix entered agreement

Read more news here.

Synaffix entered agreement  Synaffix entered agreement 

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.